ArticleInternational journal of antimicrobial agents2018
Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37.
Article in International journal of antimicrobial agents, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 118 citations in OpenAlex.
- Antibacterial and antibiofilm activity of novel nanofibers bandage formulated withChinese herbal medicines · 2026Article
- Marine-derived Peptides As Anti-biofilm and Anti-virulence Agents: Mechanistic Insights and Applications Against Microbial Pathogens.Probiotics and antimicrobial proteins · 2026Review
- Structural Modification and Conjugation Strategies of Antimicrobial Peptides for Topical Anti-Infective Applications.Antibiotics (Basel, Switzerland) · 2026Review
- Pathobiology of ESKAPE Biofilms in implant infections: current understanding and implications for future therapeutic strategies.Frontiers in cellular and infection microbiology · 2026Review
- Antibacterial and antibiofilm activity of nanoparticles inRSC advances · 2025Article
- Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Article
- Sodium dichloroisocyanurate: a promising candidate for the disinfection of resilient drain biofilm.Infection prevention in practice · 2025Article
- Anti-Biofilm Agents to OvercomePharmaceuticals (Basel, Switzerland) · 2025Review
- Comparative evaluation of antimicrobial peptides: effect on formation, metabolic activity and viability ofFrontiers in microbiology · 2025Article
- Comparative Properties of Helical and Linear Amphipathicity of Peptides Composed of Arginine, Tryptophan, and Valine.Antibiotics (Basel, Switzerland) · 2024Article
- Green Synthesis of Silver Nanoparticle fromAntibiotics (Basel, Switzerland) · 2024Article
- PRO: Environmental microbiological surveillance does support infection control in veterinary hospitals.JAC-antimicrobial resistance · 2024Article
- Discovery of Biofilm Inhibitors from the Microbiota of Marine Egg Masses.Journal of natural products · 2024Article
- Healing of Skin Wounds in Rats Using Creams Based on Symphytum Officinale Extract.International journal of molecular sciences · 2024Article
- Molecular Aspects of the Functioning of Pathogenic Bacteria Biofilm Based onInternational journal of molecular sciences · 2024Review
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Exploration of Antimicrobial Peptides in the Treatment of Gentamicin-ResistantInfection and drug resistance · 2024Article
- Review
- Optimization of antimicrobial peptides for the application against biocorrosive bacteria.Applied microbiology and biotechnology · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesBacterial biofilm-dependent infections (e.g. cystic fibrosis, surgical sites, and medical implants) are associated with enhanced drug-resistance and are thus difficult to eradicate. The goal of this study was to systematically compare three distinct classes of antimicrobial peptides (AMPs) that include the clinically used antibiotic colistin, the natural AMP LL37, the engineered cationic-AMP WLBU2, and four commonly used antibiotics with different bactericidal mechanisms (tobramycin, ciprofloxacin, ceftazidime, and vancomycin) for biofilm prevention properties.
methodsUsing biofilm-prevention assays, we detected bacterial biomass post-attachment in subinhibitory concentrations (1/3 of the minimum inhibitory concentration [MIC]) for each AMP by the crystal violet method, to distinguish the commonly known bactericidal activity from potentially distinct mechanisms of biofilm prevention. Biofilm regulatory gene expression was assessed using RT-qPCR for correlation with biofilm growth inhibition.
resultsCommonly used antibiotics at 1x MIC showed modest ESKAPE biofilm prevention while 1/3 MIC of AMPs demonstrated up to 90% biofilm prevention. WLBU2 was generally more effective in preventing bacterial attachment than colistin and LL37. Changes in bacterial biofilm regulatory gene expression were consistent with biofilm prevention.
conclusionThe data warrant further exploration of AMPs with optimized structures to fill a knowledge gap on the potential application of AMPs for difficult-to-cure bacterial biofilm-related infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.